"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Remnant of a tumor or cancer after primary, potentially curative therapy.
| Descriptor ID |
D018365
|
| MeSH Number(s) |
C04.697.700 C23.550.727.700
|
| Concept/Terms |
Neoplasm, Residual- Neoplasm, Residual
- Residual Neoplasms
- Residual Neoplasm
- Minimal Residual Disease
- Minimal Disease, Residual
- Residual Minimal Disease
- Residual Minimal Diseases
- Residual Disease, Minimal
- Minimal Residual Diseases
Residual Tumor- Residual Tumor
- Residual Tumors
- Residual Tumour
- Residual Tumours
- Tumour, Residual
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".
This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 3 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 2 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 3 | 4 |
| 2012 | 0 | 8 | 8 |
| 2013 | 1 | 4 | 5 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 5 | 6 |
| 2016 | 3 | 3 | 6 |
| 2017 | 3 | 5 | 8 |
| 2018 | 2 | 2 | 4 |
| 2019 | 4 | 6 | 10 |
| 2020 | 4 | 1 | 5 |
| 2021 | 3 | 6 | 9 |
| 2022 | 1 | 9 | 10 |
| 2023 | 0 | 5 | 5 |
| 2024 | 4 | 6 | 10 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 2025 Mar 25; 9(6):1442-1451.
-
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Dec 12; 391(23):2219-2230.
-
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. Bone Marrow Transplant. 2025 Feb; 60(2):135-143.
-
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
-
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. Radiology. 2024 09; 312(3):e232748.
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
-
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 Jul 25; 391(4):320-333.
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
-
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. Gynecol Oncol. 2024 07; 186:17-25.
-
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77.